Rheumatoid arthritis is an autoimmune inflammatory disease in which the immune system attacks joint lining tissues, causing chronic pain, swelling, and stiffness. It most commonly affects small and medium joints and can also involve extra-articular organs such as the lungs, heart, and eyes.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Kyverna Therapeutics reports positive long-term follow-up results for its CAR-T therapy miv-cel in generalized myasthenia gravis, with plans to submit a biologics license application in the first half of 2026. The company has $279.3 million in cash providing runway into 2028 to fund launch and Phase 3 trials.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion to USD 5.73 billion by 2035 at a 19% CAGR. Monoclonal antibodies hold almost 55% of market share, while oncological disorders dominate demand.
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
Dr. Reddy's said the FDA accepted for review its 351(k) BLA for DRL_AB, a proposed interchangeable biosimilar to ORENCIA. The application covers an IV formulation for RA, PsA and pJIA.
The FDA has eased biosimilar approval procedures as these therapies have generated $56 billion in savings since 2015. New guidance eliminates comparative efficacy studies, potentially saving manufacturers $100 million per product and cutting development time by 50%. Despite growth to 23% of the biologics market, a "biosimilar void" threatens $232 billion in missed savings over the next decade.
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Diacerein, an anthraquinone derivative, shows promise as a disease-modifying agent in rheumatoid arthritis through its anti-inflammatory and chondroprotective actions, with combination therapy appearing to enhance therapeutic benefits.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07582185 |
Tdose Binding and Tocilizumab |
NOT_YET_RECRUITING | PHASE4 |
| NCT07571993 |
Rheumatoid Arthritis Remission Screening and Prospective Surveillance |
RECRUITING | |
| NCT07566351 |
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis |
RECRUITING | PHASE2 |
| NCT07558850 |
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases |
RECRUITING | NA |
| NCT07554820 |
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL |
RECRUITING | PHASE4 |
| NCT07534332 |
Disulfiram in Rheumatoid Arthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07515638 |
Immun4Cure Cohort of Autoimmune Diseases |
NOT_YET_RECRUITING | |
| NCT07497282 |
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07491016 |
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis |
RECRUITING | |
| NCT07489326 |
The SetPoint System Safety & Performance Post-Approval Study |
NOT_YET_RECRUITING |
